Cancer profiling is a promising market and is witnessing significant growth in the healthcare industry. It is poised to grow rapidly in a range of application areas, including biomarker discovery and prognosis. The global market is valued at $14.99 billion in 2013 and is expected to reach $35.03 billion by 2018.
A list of tests (for example, Barium X-ray, Blood tests, Bone marrow, Cystoscopy, Lumbar puncture) is available, used for diagnosing specific types of cancer. Also, there are different treatment options for cancer, including chemotherapy, hormone therapy, surgery, radiotherapy, bisphosphonates, bone marrow and stem cell transplants, and biological therapies. Despite the availability of different treatment options, profiling a tumor, that is, knowledge about a patient's cancer profile may identify genomic alterations that will help the physician to guide the patient to a systemic therapy with a higher likelihood of success. This will rule out those that are unlikely to be successful, on an individual basis, thereby minimizing the trial and error process.
Every cancer cell has got its own pattern of active genes and proteins; therefore, molecular profiling tests for a number of different biomarkers in the DNA of a tissue sample will assist in better diagnosing and staging the cancer on an individual basis. This provides the doctors with better information to develop a personalized treatment plan for a patient, which is known as personalized medicine.
There are quite a number of research groups working on diverse applications of tumor profiling targeting different cancer types, particularly in studying key target molecules involved in the pathogenesis. Hundreds of research articles have been published and a lot of patents granted and filed for this field of biology.
The market is analyzed both in terms of qualitative, that is, technological and quantitative, that is, revenue and perspectives. The technological analysis includes discussion on the advantages and capabilities of cancer profiling technologies and the various applications where tumor profiling can find a strong position in the healthcare industry. The market revenue analysis includes market segmentation and the expected market position by 2018, with the projected growth rate.
The market is classified by geography, applications, technologies, and segment types. The technologies section is further segmented into Next-Generation Sequencing, Quantitative PCR, Immunohistochemistry, FISH/CISH, and Microarray. Though personalized medicine is highlighted as the prime application area of cancer/tumor profiling, there are many opportunities in Diagnostics, Biomarker Discovery, Prognosis, and Research applications.
Besides a discussion on the properties and advantages of cancer profiling in the technological analysis, the basics on the correlation of cancer with genomics, proteomics, Metabolomics, and epigenetics are also discussed. Further, the research network including academic universities and biotech companies with their research contributions are also provided. The complete value chain of the tumor profiling market is schematically represented and the significance of each stakeholder has been briefed.
Apart from the technological and market analysis, the investor climate has been assessed by tracking the complete investor network and collecting data on funds/grants and investments made towards the cancer profiling. Insights on current and future technological investment trends have also been discussed.
The adoption and developmental potential of this technology market has been discussed on a geographic basis, that is, North America, Europe, Asia, and Rest of the World, by taking select countries that are poised to have a greater market value during the for